Premium
Lipid‐lowering therapy following major cardiac events: progress and deficits
Author(s) -
Mudge Alison M,
Brockett Rodd,
Foxcroft Katie F,
Denaro Charles P
Publication year - 2001
Publication title -
medical journal of australia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 131
eISSN - 1326-5377
pISSN - 0025-729X
DOI - 10.5694/j.1326-5377.2001.tb143061.x
Subject(s) - medicine , medical prescription , unstable angina , myocardial infarction , emergency medicine , retrospective cohort study , pharmacotherapy , angina , hospital discharge , intensive care medicine , pharmacology
Objective To assess hospital prescribing of lipid‐lowering agents in a tertiary hospital, and examine continuation of, or changes to, such therapy in the 6–18 months following discharge. Design Retrospective data extraction from the hospital records of patients admitted from October 1998 to April 1999. These patients and their general practitioners were then contacted to obtain information about ongoing management after discharge. Setting Tertiary public hospital and community. Participants 352 patients admitted to hospital with acute myocardial infarction or unstable angina, and their GPs. Main outcome measures Percentage of eligible patients discharged on lipid‐lowering therapy and percentage of patients continuing or starting such therapy 6–18 months after discharge. Results 10% of inpatients with acute coronary syndromes did not have lipid‐level estimations performed or arranged during admission. Documentation of lipid levels in discharge summaries was poor. Eighteen per cent of patients with a total serum cholesterol level greater than 5.5 mmol/L did not receive a discharge prescription for a cholesterol‐lowering agent. Compliance with treatment on follow‐up was 88% in the group discharged on treatment. However, at follow‐up, 70% of patients discharged without therapy had not been commenced on lipid‐lowering treatment by their GPs. Conclusions Prescribing of lipid‐lowering therapy for secondary prevention following acute coronary syndromes remains suboptimal. Commencing treatment in hospital is likely to result in continuing therapy in the community. Better communication of lipid‐level results, treatment and treatment aims between hospitals and GPs might encourage optimal treatment practices.